Reata Pharma kidney drug meets study goals, stock halted

Reata Pharmaceuticals Inc. shares were halted in the extended session Monday as the biotech drug developer reported positive results from a late-stage kidney disease treatment study. Reata shares were flat, following a 1% rise to close the regular session at $213.67. In a Phase 3 study, Reata said its drug bardoxolone treated patients with chronic kidney disease caused by Alport syndrome significantly better than a placebo in primary and secondary endpoints. Alport syndrome is a rare, genetic form of kidney disease that causes end-stage kidney failure in a majority of patients.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.